NJ-MERCK/MSD-ANIMAL
MSD Animal Health, known as Merck Animal Health in the United States and Canada, today announced plans to purchase a new manufacturing facility in Krems an der Donau, Austria with the intention to expand its global vaccine manufacturing capacity. The facility, currently owned by Shire plc., was built in 2002 and will add to the company’s impressive global manufacturing capabilities.
“This new manufacturing site is ideally located in central Europe. It provides MSD Animal Health additional manufacturing resources and advanced technology platforms to meet the growing demand for our vaccine products that prevent disease and keep animals healthy while positioning us for strong long-term growth,” stated Joseph Morrissey, senior vice president, operations, MSD Animal Health.
“We are excited to expand our footprint to Krems,” stated Dr. Hans-Günther Dittrich, vice president, Europe, Russia, North Africa, Middle East region. “Krems is the home to several distinct universities, and a rich tradition as an economic center for bio-pharmaceuticals. It is a great opportunity for us to tap into the innovative science in the area.”
MSD Animal Health has a substantial global manufacturing footprint and is a leader in animal health vaccines with a range of global vaccines products for animal health diseases.
MSD Animal Health intends to immediately begin renovating the facility and expects to be ready for production in the coming years. Additional terms of the deal will not be disclosed.
About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™ , MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn .
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov ).
View source version on businesswire.com: http://www.businesswire.com/news/home/20170807005047/en/
Contact:
Merck
Media
Pam Eisele, 267-305-3558
Pamela.eisele@merck.com
or
Noreen
Verbrugge, 973-937-5450
Noreen.verbrugge@merck.com
or
Investor
Relations
Amy Klug, 908-740-1898
Amy.klug@merck.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis discloses Corticorelin as active substance of C-PTBE-0123.5.2025 07:00:00 CEST | Press release
Corticorelin Market Opportunity in Peritumoral Brain Edema (PTBE) expected to exceed USD 1 billion; Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema in association with malignant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster drug with that can contribute significantly to the quality of life of many patients, combined with the potential of maintaining the efficacy of immunotherapies for these patients, is very motivating and exciting,” said Dr. Roland Rutschmann, Curatis CEO. Key statements Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively imp
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 202522.5.2025 23:43:00 CEST | Press release
Data from Phase 3 MANEUVER study demonstrating significant improvements in physical function and symptoms in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, to be featured in oral presentationLatest results for potential first-in-class anti-CEACAM5 ADC precemtabart tocentecan (M9140) highlight strong rationale for further development in colorectal cancer (CRC)Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of the rare tumor TGCT, as well as data from both company- and investigator-sponsored studies highlighting the company’s focus on advancing differentiated molecules to tackle some of the most challenging cancers.
Cooperation between Topcon Positioning Systems and Amberg Technologies Ltd.22.5.2025 22:17:00 CEST | Press release
Topcon Positioning Systems and Amberg Technologies Ltd. have initiated a close collaboration to enable interoperability between Topcon’s sensor solutions and Amberg Technologies’ software and hardware platforms for rail and tunnel applications. This marks the first step towards offering fully integrated solutions to our shared customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522363239/en/ Luc Le Maire, Senior Vice President, Topcon (left) and Johannes Mueller, CEO, Amberg Technologies. About Topcon Positioning Systems Topcon Positioning Systems is an industry-leading designer, manufacturer and distributor of precision measurement and workflow solutions for the global construction, geospatial and agriculture markets. Topcon Positioning Systems is headquartered in Livermore, California, U.S. (topconpositioning.com, LinkedIn, X, Facebook, Instagram). Its European head office is in Zoetermeer, Netherlands. Topcon Cor
LBT Holdings Ltd. Acquires Gonet Bank & Trust Limited, Introducing Bank of Nassau to Uphold the Finest Traditions of Private Banking22.5.2025 18:29:00 CEST | Press release
LBT Holdings Ltd., in partnership with Gonet SA, is pleased to announce the successful acquisition of Gonet Bank & Trust Limited, a distinguished Bahamas-based private bank formerly owned by Gonet SA. The transaction, which has received full regulatory approval from the Swiss Financial Market Supervisory Authority (FINMA), the Central Bank of The Bahamas (CBOB), and The Securities Commission of The Bahamas (SCB), marks a significant milestone for both organizations. Effective immediately, LBT Holdings Ltd. assumes 100% ownership of Gonet Bank & Trust Limited. As part of this strategic transition, Gonet Bank & Trust Limited will be rebranded as Bank of Nassau 1982 Limited, reflecting its renewed vision and commitment to excellence in private banking and wealth management. This acquisition strengthens the position of all parties in the global financial services sector, enabling expanded service offerings while upholding the highest standards of client-centric banking. Bank of Nassau 1982
Andersen Global indvier medlemsfirmaer i Usbekistan og styrker sin tilstedeværelse i Centralasien22.5.2025 16:34:00 CEST | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse i Centralasien med tilføjelsen af Andersen i Usbekistan, hvilket er en del af den fortsatte udvidelse af organisationens kapaciteter i regionen. Firmaet blev grundlagt i 2009 under navnet Virtus Leo og ledes af den administrerende partner Alisher Zaynutdinov. Siden 2021 har det været samarbejdspartner med Andersen Global. Teamet tilbyder tjenester inden for skatte- og juraforhold inden for en bred vifte af sektorer, herunder overholdelse af skattelovgivningen for selskabser og enkeltpersoner, rådgivning om direkte og indirekte skat, transferpriser, ledelsesrapportering og -analyse, selskabsledelse, konkurrenceret og antitrust, selskabs- og bankret, arbejds- og ansættelsesret, retssager og undersøgelser, fusioner og opkøb, fast ejendom, energi, immaterialret samt familieret. "I kraft af vores professionalisme, gennemsigtighed og evne til at se løsninger samt analytiske tilgang til alle opgaver er vi godt positioneret til at rådgive vores klien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom